- The FDA has placed a clinical hold on Miromatrix Medical Inc’s (NASDAQ:MIRO) miroliverELAP Investigational New Drug (IND) application for acute liver failure.
- The miroliverELAP IND application was submitted in mid-November. The FDA indicated they would provide an official clinical hold letter to Miromatrix within 30 days.
- Miromatrix plans to provide additional updates pending communication with the FDA.
- Miromatrix Medical is a life sciences company that has developed a proprietary perfusion technology platform for bioengineering organs to address the shortage of available human organs.
- The Company’s initial development focus is on human livers and kidneys.
- Miromatrix is scaling to clinical-sized implants and recently successfully revascularized a decellularized porcine liver graft with human vascular cells and sustaining perfusion for 15 days post-transplantation.
- Price Action: MIRO shares closed 32.90% lower at $2.75 during premarket trading on Thursday.
